DCAL167.18

Dishman Carbogen Amcis Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,621 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations586.6651.1654.7523.8789.0682.3716.3708.1652.7719.8851.4677.6
Other Income8.56.17.21.46.75.68.024.88.16.716.418.2
Total Income595.1657.1661.9525.2795.7688.0724.3732.8660.8726.5867.8695.8
Expenses
+ Cost of Materials Consumed137.9202.5158.761.1216.1161.6154.2205.634.1127.8120.4144.7
+ Changes in Inventories-3.5-84.422.75.2-25.5-62.8-8.2-107.50.213.714.6-30.4
+ Employee Benefit Expense283.1309.2320.8316.8319.7332.1324.9351.9332.9355.9406.2389.1
+ Finance Costs27.533.131.031.936.648.842.142.842.345.843.337.1
+ Depreciation & Amortisation75.080.485.070.672.172.079.181.484.184.488.890.7
+ Other Expenses108.3182.789.9111.6131.6111.392.8117.4136.5109.3147.3114.2
Total Expenses628.3723.4708.0597.3750.6663.0684.9691.5630.2736.9820.5745.3
EBITDA60.941.162.729.0147.2140.1152.7140.7148.9113.1163.060.1
EBIT-14.2-39.3-22.3-41.675.168.273.659.364.828.774.2-30.6
Profit
PBT before Exceptional Items-33.2-66.3-46.1-72.145.125.039.541.330.5-10.447.3-49.5
+ Exceptional Items-3.10.0-3.1-5.4-3.02.0-11.8-2.70.00.0-1.2-1.7
Pretax Income-36.3-66.3-49.2-77.642.127.127.738.730.5-10.446.1-51.2
+ Current Tax7.40.826.30.921.026.6-4.818.63.511.225.83.3
+ Deferred Tax-2.7-7.5-5.6-0.9-12.0-4.2-10.6-3.4-38.2-8.6-1.43.3
Tax Expense4.6-6.720.70.09.022.4-15.415.3-34.72.524.46.7
Net Income-40.9-59.6-69.9-77.633.14.643.123.465.3-13.021.7-57.9
+ Net Income — Continuing Ops-40.9-59.6-69.9-77.633.14.643.123.465.3-13.021.7-57.9
+ Other Comprehensive Income-55.6274.8-288.66.0147.8-173.3220.4328.6116.276.1227.019.3
Total Comprehensive Income-96.5215.1-358.5-71.6180.9-168.7263.5352.0181.463.2248.8-38.6
Net Income to Common-40.9-59.6-69.9-77.633.14.643.123.465.3-13.021.7-57.9
Per Share
Basic EPS-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Diluted EPS-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Other Comprehensive Income — detail
+ Other Comprehensive Income220.4328.6116.276.1227.019.3
+ Items NOT to be Reclassified to P&L-18.1-0.1-98.70.0-75.30.0101.40.27.8-3.432.70.0
+ Tax on Items NOT to be Reclassified-3.40.10.80.110.50.0
+ Tax on Items NOT to be Reclassified — alt tag0.10.00.00.00.00.1
+ Items to be Reclassified to P&L-36.4256.8-168.56.2213.1-170.6119.0312.299.076.3203.929.2
+ Tax on Items to be Reclassified3.5-16.3-10.1-3.3-1.09.9
+ Tax on Items to be Reclassified — alt tag1.2-18.121.40.3-10.02.7
Comprehensive Income — Owners of Parent-96.5215.1-358.5-71.6180.9-168.7263.3328.6116.263.2227.019.3
Comprehensive Income — Non-controlling Interests0.00.00.00.00.00.0352.0181.40.0248.8-38.6
Per Share — as-filed variants
Basic EPS — Continuing Operations-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Diluted EPS — Continuing Operations-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit452.2533.0473.3457.4598.5583.5570.4610.0618.3578.3716.5563.4
Gross Margin %77.1081.8672.2987.3375.8585.5279.6386.1594.7480.3484.1583.14
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-33.2-66.3-46.1-72.145.125.039.541.330.5-10.447.3-49.5
− Exceptional Items (reconciliation)-3.10.0-3.1-5.4-3.02.0-11.8-2.70.00.0-1.2-1.7
Net Income Adj (tax-effected)-37.9-59.6-66.8-72.135.43.854.825.065.3-13.022.3-56.2
EPS Adj-2.42-3.80-4.26-4.602.260.253.501.594.16-0.831.42-3.58
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Filed Debt Equity0.000.000.000.000.000.000.000.000.000.00
Filed Dscr0.020.010.010.020.020.020.010.020.010.01
Filed Iscr0.030.020.020.030.030.030.030.030.030.03
Paid Up Equity Capital31.431.431.431.431.431.431.431.431.431.431.431.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.